MeiraGTx's innovative gene therapies for ocular diseases & more are backed by strong clinical data and funding. Click here to find out why MGTX stock is a Buy.

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3 ...